¦ ARIA (TP$8, Neutral) – Call on August 6 at 8:30am EST: The primary metric for ARIA is its top-line sales. We forecast US Iclusig sales of $15.9M (up from $8.0M in Q1) vs consensus of $11.1M. The primary focus will be (1) Iclusig re-launch in the US (topline number, patients on drug, line of therapy), (2) plans on restarting trials and additional trials now that partial clinical hold was lifted; (3) plans to move to flat pricing across doses; (4) progress on EU roll-out, including the Pharmacovigilance Risk Assessment Committee (PRAC) delay that was recently announced. We forecast Q2 GAAP EPS of ($0.26) and revenue of $16.0M vs. consensus of ($0.29) and $13.7
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.